Allogeneic stem cell transplantation for myelodysplastic syndrome

Area of Science:

• Hematology
• Oncology
• Transplant Immunology

Background:

• Myelodysplastic syndromes (MDS) primarily affect older adults with comorbidities.
• Stem cell transplantation (SCT) is the only curative option for MDS.
• Reduced-intensity conditioning (RIC) regimens have expanded SCT eligibility for older MDS patients.

Purpose of the Study:

• To review current advancements in SCT for MDS.
• To identify challenges and future directions for improving SCT outcomes in MDS.

Main Methods:

• Review of recent literature on SCT for MDS.
• Analysis of strategies to mitigate risks like non-relapse mortality (NRM) and relapse.
• Discussion of novel approaches including pre-transplant chemotherapy and post-transplant immunotherapy.

Main Results:

• SCT outcomes in MDS remain limited by high overall mortality (>50%), primarily due to relapse and NRM.
• RIC regimens have improved SCT accessibility for elderly MDS patients.
• New strategies like individualized transplant approaches, pre-transplant chemotherapy, and post-transplant immunotherapy show promise.

Conclusions:

• Optimizing SCT for MDS requires better immune reconstitution and graft-versus-leukemia (GVL) enhancement while minimizing graft-versus-host disease (GVHD).
• Expanding the donor pool and developing risk-adapted regimens are crucial for improving outcomes in elderly MDS populations.
• Further research is essential to refine SCT protocols and improve survival rates for MDS patients.